Skip to content
MARKETS / NASDAQ / NXTS
NASDAQ · PHARMACEUTICAL PREPARATIONS

Nexentis Technologies Inc. NXTS

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$-4.0M
$-3.8M
In brief

What this company does

We are focused on sustainable operations in various industries such as solar projects, and oncology biotechnology. Our activities are advancing innovative oncology solutions through MitoCareX to improve cancer treatment outcomes. Solterra Renewable Energy Ltd., an Israeli corporation (“Solterra”), operates in the solar energy sector and presents certain investment opportunities in solar photovoltaic (“PV”) projects. Solterra’s business strategy primarily involves selling renewable energy projects to third parties at various stages of development, from the initial land identification and project advancement through construction, operation, or sale to a third party.

Written from the business description in Nexentis Technologies Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.2 · Net income -5.2
-2.5M-5.0M20182019202020212022202320242025
Compound annual growth
−21.7%
+3.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +3.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2024 · Operating -1563.3% · Net -2546.2%
-1000%-2000%20182019202020212022202320242025
ROE
FY2025 · ROE -38.6%
-50%-100%-150%20182019202020212022202320242025

Each USD of equity lost 39 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -3.8
-2M-4M20182019202020212022202320242025

Total assetsUSD 20.4M
EquityUSD 16.0M
CashUSD 3.8M
Gross debtUSD 1.4M
Net debtUSD -2.4M
Current ratio4.19×

The company holds more cash than debt.

The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018
Revenue $B·0.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.0·······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0··−0.0−0.0·−0.0−0.0
EPS, diluted $−8.61−27.74−5.43−10.85−2.06−1.05−1.38−0.05
Dividend / sh $········
Payout %········
ROE %−38.6−92.5−105.8−93.1−159.4··−163.5
Shares out B0.000.000.000.000.000.000.000.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 39 reconciliationsAUDITED

Reconciled in 8 of 19 fiscal years. 56 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image